From the publishers of JADPRO

Biomarkers in NSCLC Resource Center

Advertisement

ZFHX3 Mutation as a Protective Biomarker for Immune Checkpoint Blockade in Non–Small Cell Lung Cancer

Last Updated: Friday, October 22, 2021

The authors found that ZFHX3 mutations are closely related to longer overall survival in NSCLC patients treated with immune checkpoint inhibitors (ICIs), suggesting that ZFHX3 mutations be used as a novel predictive marker in guiding NSCLC ICI treatment.

Cancer Immunology, Immunotherapy
Advertisement
News & Literature Highlights
Advertisement
Advertisement